New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus.
Clin Microbiol Infect. 2009 Dec;15(s7ESCMID Consensus concerning MRSA.):44-52
Authors: Bouza E
In recent years, a marked increase in the incidence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has occurred in many countries. This review addresses the effectiveness and limitations of drugs classically used for the treatment of MRSA, e.g. vancomycin, and also newer anti-MRSA antimicrobials, e.g. second-generation glycolipopeptides, tigecycline, and beta-lactams.
PMID: 19951334 [PubMed - as supplied by publisher]